Evaluation of platelet deposition and neointimal hyperplasia of heparin-coated small-caliber ePTFE grafts in a canine femoral artery bypass model

Journal of Surgical Research

Volumn 118, Issue 1, 2004, Pages 45-52

  Lin, Peter H ^a,b   Bush, Ruth L ^a,b   Yao, Qizhi ^a,b   Lumsden, Alan B ^a,b   Chen, Changyi ^a,b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Heparin; Intimal hyperplasia; PTFE vascular graft

Indexed keywords

HEPARIN; INDIUM 111;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY BYPASS; ARTERY INTIMA PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DOG; EXPERIMENTAL MODEL; FEMORAL ARTERY; GRAFT PATENCY; IMAGE ANALYSIS; ISOTOPE LABELING; MORPHOMETRICS; NONHUMAN; POLITEF IMPLANT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SCINTILLATION CAMERA; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION;

ANASTOMOSIS, SURGICAL; ANIMALS; ANTICOAGULANTS; BLOOD PLATELETS; BLOOD VESSEL PROSTHESIS; COATED MATERIALS, BIOCOMPATIBLE; DOGS; FEMORAL ARTERY; HEPARIN; HYPERPLASIA; POLYTETRAFLUOROETHYLENE; TIME FACTORS; TUNICA INTIMA; VASCULAR PATENCY;

EID: 1842839912     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jss.2003.12.026     Document Type: Conference Paper

References (36)

1. Sayers R.D., Raptis S., Berce M., Miller J.H. Long-term results of femorotibial bypass with vein or polytetrafluoroethylene. Br. J. Surg. 85:1998;934.
2. Biancari F., Railo M., Lundin J., Alback A., Kantonen I., Lehtola A., Lepantalo M. Redo bypass surgery to the infrapopliteal arteries for critical leg ischaemia. Eur. J. Vasc. Endovasc. Surg. 21:2001;137.
3. Clowes A.W., Reidy M.A., Clowes M.M. Mechanisms of stenosis after arterial injury. Lab. Invest. 49:1983;208.
4. Guyton J.R., Rosenberg R.D., Clowes A.W., Karnovsky M.J. Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ. Res. 46:1980;625.
5. Clowes A.W., Karnowsky M.J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 265:1977;625.
6. Letourneur D., Caleb B.L., Castellot J.J. Jr. Heparin binding, internalization, and metabolism in vascular smooth muscle cells: I. Upregulation of heparin binding correlates with antiproliferative activity. J. Cell. Physiol. 165:1995;676.
7. Clowes A.W., Clowes M.M., Kirkman T.R., Jackson C.L., Au Y.P., Kenagy R. Heparin inhibits the expression of tissue-type plasminogen activator by smooth muscle cells in injured rat carotid artery. Circ. Res. 70:1992;1128.
8. Chen C., Lumsden A.B., Hanson S.R. Local infusion of heparin reduces anastomotic neointimal hyperplasia in aortoiliac expanded polytetrafluoroethylene bypass grafts in baboons. J. Vasc. Surg. 31:2000;354.
9. Lin P.H., Chronos N.A., Marijianowski M.M., Chen C., Conklin B., Bush R.L., Lumsden A.B., Hanson S.R. Carotid stenting using heparin-coated balloon-expandable stent reduces intimal hyperplasia in a baboon model. J. Surg. Res. 112:2003;84.
10. Lin P.H., Chronos N.A., Marijianowski M.M., Chen C., Bush R.L., Conklin B., Lumsden A.B., Hanson S.R. Heparin-coated balloon-expandable stent reduces intimal hyperplasia in the iliac artery in baboons. J. Vasc. Interv. Radiol. 14:2003;603.
11. Sanchez J., Elgue G., Riesenfeld J., Olsson P. Control of contact activation on end-point immobilized heparin The role of antithrombin and the specific antithrombin-binding sequence. J. Biomed. Mater. Res. 29:1995;655.
12. Riesenfeld J., Olsson P., Sanchez J., Mollnes T.E. Surface modification with functionally active heparin. Med. Device Technol. 6:1995;24.
13. Chen C., Mattar S.G., Hughes J.D., Pierce G.F., Cook J.E., Ku D.N., Hanson S.R., Lumsden A.B. Recombinant mitotoxin basic fibroblast growth factor-saporin reduces venous anastomotic intimal hyperplasia in the arteriovenous graft. Circulation. 94:1996;1989.
14. Daugherty M.E., Sachatello C.R., Ernst C.B. Improved treatment of popliteal arterial injuries using anticoagulation and extra-anatomic reconstruction. Arch. Surg. 113:1978;1317.
15. Whiffen J.D., Dutton R., Young W.P., Gott V.L. Heparin application to graphite-coated intravascular prostheses. Surgery. 56:1964;404.
16. Ferguson J.J., Waly H.M., Wilson J.M. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition. Am. Heart J. 135:1998;S35.
17. Rohrer M.J., Kestin A.S., Ellis P.A., Barnard M.R., Rodino L., Breckwoldt W.L., Li J.M., Michelson A.D. High-dose heparin suppresses platelet alpha granule secretion. J. Vasc. Surg. 15:1992;1000. discussion 1008.
18. Xia C.Q., Kao K.J. Heparin induces differentiation of CD1a+ dendritic cells from monocytes Phenotypic and functional characterization. J. Immunol. 168:2002;1131.
19. Tayama E., Hayashida N., Akasu K., Kosuga T., Fukunaga S., Akashi H., Kawara T., Aoyagi S. Biocompatibility of heparin-coated extracorporeal bypass circuits new heparin bonded bioline system. Artif. Organs. 24:2000;618.
20. Dewanjee M.K., Palatianos G.N., Kapadvanjwala M., Hsu L.C., Novak S., Balantino G., Serafini A.N., Dietrich W.D., Sfakianakis G.N. Neutrophil dynamics and retention in lung, oxygenator, and arterial filter during cardiopulmonary bypass in a pig model. ASAIO J. 40:1994;M547.
21. Serruys P.W., Emanuelsson H., van der Giessen W., Lunn A.C., Kiemeney F., Macaya C., Rutsch W., Heyndrickx G., Suryapranata H., Legrand V., Goy J.J., Materne P., Bonnier H., Morice M.C., Fajadet J., Belardi J., Colombo A., Garcia E., Ruygrok P., de Jaegere P., Morel M.A. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. Circulation. 93:1996;412.
22. Fager G., Camejo G., Bondjers G. Heparin-like glycosaminoglycans influence growth and phenotype of human arterial smooth muscle cells in vitro. I. Evidence for reversible binding and inactivation of the platelet-derived growth factor by heparin. In Vitro Cell Dev. Biol. 28A:1992;168.
23. Au Y.P., Kenagy R.D., Clowes M.M., Clowes A.W. Mechanisms of inhibition by heparin of vascular smooth muscle cell proliferation and migration. Haemostasis. 23:(Suppl. 1):1993;177.
24. Reilly C.F., Kindy M.S., Brown K.E., Rosenberg R.D., Sonenshein G.E. Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle. J. Biol. Chem. 264:1989;6990.
25. Castellot J.J. Jr, Wong K., Herman B., Hoover R.L., Albertini D.F., Wright T.C., Caleb B.L., Karnovsky M.J. Binding and internalization of heparin by vascular smooth muscle cells. J. Cell. Physiol. 124:1985;13.
26. Ottlinger M.E., Pukac L.A., Karnovsky M.J. Heparin inhibits mitogen-activated protein kinase activation in intact rat vascular smooth muscle cells. J. Biol. Chem. 268:1993;19173.
27. Herbert J.M., Clowes M., Lea H.J., Pascal M., Clowes A.W. Protein kinase C alpha expression is required for heparin inhibition of rat smooth muscle cell proliferation in vitro and in vivo. J. Biol. Chem. 271:1996;25928.
28. Au Y.P., Dobrowolska G., Morris D.R., Clowes A.W. Heparin decreases activator protein-1 binding to DNA in part by posttranslational modification of Jun B. Circ. Res. 75:1994;15.
29. Nugent M.A., Karnovsky M.J., Edelman E.R. Vascular cell-derived heparan sulfate shows coupled inhibition of basic fibroblast growth factor binding and mitogenesis in vascular smooth muscle cells. Circ. Res. 73:1993;1051.
30. Reilly C.F., Fritze L.M., Rosenberg R.D. Antiproliferative effects of heparin on vascular smooth muscle cells are reversed by epidermal growth factor. J. Cell. Physiol. 131:1987;149.
31. McCaffrey T.A., Falcone D.J., Brayton C.F., Agarwal L.A., Welt F.G., Weksler B.B. Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex. J. Cell. Biol. 109:1989;441.
32. Au Y.P., Montgomery K.F., Clowes A.W. Heparin inhibits collagenase gene expression mediated by phorbol ester-responsive element in primate arterial smooth muscle cells. Circ. Res. 70:1992;1062.
33. Faxon D.P., Spiro T.E., Minor S., Cote G., Douglas J., Gottlieb R., Califf R., Dorosti K., Topol E., Gordon J.B. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation. 90:1994;908.
34. Laskey M.A., Deutsch E., Hirshfeld J.W. Jr, Kussmaul W.G., Barnathan E., Laskey W.K. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus. Am. J. Cardiol. 65:1990;179.
35. Au Y.P., Kenagy R.D., Clowes A.W. Heparin selectively inhibits the transcription of tissue-type plasminogen activator in primate arterial smooth muscle cells during mitogenesis. J. Biol. Chem. 267:1992;3438.
36. Devine C., Hons B., McCollum C. Heparin-bonded Dacron or polytetrafluoroethylene for femoropopliteal bypass grafting A multicenter trial. J. Vasc. Surg. 33:2001;533.